Table 3.
Variables associated with local recurrence.
| Variable | Univariate | Multivariate | ||
|---|---|---|---|---|
| p Value | HR (95% CI) | p Value | HR (95% CI) | |
| Group | 0.187 | 1.376 | - | - |
| (SBRT vs. CCRT) | (0.847–2.212) | |||
| Age | 0.803 | 0.997 | - | - |
| (0.976–1.019) | ||||
| Gender | 0.038 | 0.585 | - | - |
| (M vs. F) | (0.353–0.972) | |||
| ECOG PS | 0.622 | 1.281 | - | - |
| (0–1 vs. 2) | (0.479–3.430) | |||
| Pre-RT CA19-9 | 0.022 | 0.564 | 0.080 | 0.631 |
| (≤140 vs. >140) | (0.345–0.920) | (0.377–1.057) | ||
| Tumor location | 0.209 | 0.733 | - | - |
| (Head vs. Body/tail) | (0.451–1.191) | |||
| Tumor size | 0.021 | 0.558 | 0.073 | 0.623 |
| (≤40 vs. >40) | (0.341–0.915) | (0.371–1.046) | ||
| Clinical N stage | 0.204 | 1.399 | - | - |
| (N0 vs. N+) | (0.834–2.346) | |||
| Abutting the stomach/duodenum | 0.882 | 1.044 | - | - |
| (No vs. Yes) | (0.588–1.854) | |||
| Induction CTx | 0.796 | 0.937 | - | - |
| (No vs. Yes) | (0.574–1.530) | |||
| Induction CTx duration | 0.762 | 0.929 | - | - |
| (≤6 months vs. >6 months | (0.575–1.500) | - | ||
| RT dose (EQD2) | 0.542 | 1.010 | - | - |
| (0.978–1.044) | - | - | ||
| Resection | 0.971 | 0.983 | - | - |
| (No vs. Yes) | (0.395–2.445) | - | ||
Abbreviations: SBRT, stereotactic body radiotherapy; CCRT, concurrent chemoradiotherapy; ECOG PS, Eastern Cooperative Oncology Group performance status; RT, radiotherapy; CA19-9, carbohydrate antigen 19-9; CTx, chemotherapy; EQD2, equivalent dose in 2 Gy per fraction.